Novo Nordisk renews cycling team deal; Amgen taps 'champions' of cancer;

> Novo Nordisk ($NVO) has re-upped on its sponsorship for an all-diabetes professional cycling team, extending the deal with Team Novo Nordisk to 5 years. Report

> Amgen ($AMGN) has plucked 10 "champion" cancer survivors, patients, caregivers and advocates as part of its Breakaway from Cancer awareness push; the winners will appear with Joan Lunden at the California company's Tour of California bike race. Release

> Bayer tapped a New Jersey woman, Patricia Middings, as the winner of its "Breathless Moments" photo contest, part of an awareness campaign for chronic thromboembolic pulmonary hypertension. Release

> Jordan's Hikma Pharmaceuticals launched a caffeine citrate injection, Cafcit, to treat apnea in premature infants. Report

> Sucampo Pharmaceuticals inked a deal with Gloria Pharma to sell the bowel drug Amitiza in China. Report

> Merck KGaA and its partner Threshold Pharmaceuticals won FDA fast-track review for their treatment for advanced pancreatic cancer, evofosfamide. Report

And Finally... When can doctors confidently say leukemia is "cured"? Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?